keyword
https://read.qxmd.com/read/38411318/immunogenicity-of-avelumab-in-patients-with-metastatic-merkel-cell-carcinoma-or-advanced-urothelial-carcinoma
#21
JOURNAL ARTICLE
Ping Hu, Haiqing Isaac Dai, James Bourdage, Dongli Zhou, Ky Trang, Karey Kowalski, Carlo Bello, Jennifer Hibma, Akash Khandelwal, Kyra Cowan, Jennifer Dong, Karthik Venkatakrishnan, Wei Gao
Like other monoclonal antibodies, immune checkpoint inhibitors may be immunogenic in some patients, potentially affecting pharmacokinetics (PKs) and clinical outcomes. In post hoc analyses, we characterized antidrug antibody (ADA) development with avelumab monotherapy in patients with metastatic Merkel cell carcinoma (mMCC) from the JAVELIN Merkel 200 trial (first-line [1L; N = 116] and second-line or later [≥2L; N = 88] cohorts) or with advanced urothelial carcinoma (aUC) from the JAVELIN Bladder 100 (1L maintenance [N = 350]) and JAVELIN Solid Tumor (≥2L [N = 249]) trials...
March 2024: Clinical and Translational Science
https://read.qxmd.com/read/38401915/precision-oncology-in-melanoma-and-skin-cancer-surgery
#22
REVIEW
Shoshana Levi, Hannah Bank, John Mullinax, Genevieve Boland
There has been perhaps no greater advance in the prognosis of solid tumors in the last decade than for patients with metastatic melanoma. This is due to significant improvements in treatment based on two key components of melanoma tumor biology (1) the identification of driver mutations with therapeutic potential and (2) the mechanistic understanding of a tumor-specific immune response. With breakthrough findings in such a relatively short period of time, the treatment of patients with metastatic melanoma has become intensely personalized...
April 2024: Surgical Oncology Clinics of North America
https://read.qxmd.com/read/38401116/head-and-neck-merkel-cell-carcinoma-therapeutic-benefit-of-adjuvant-radiotherapy-for-nodal-disease
#23
JOURNAL ARTICLE
Randall J Harley, Megan Lyden, Seetha Aribindi, Leandro Socolovsky, Earl H Harley
OBJECTIVES: To evaluate the therapeutic effect of post-operative radiotherapy (PORT) with respect to nodal status among patients with head and neck Merkel cell carcinoma (HNMCC). METHODS: In this retrospective study, we queried Surveillance, Epidemiology, and End Results (SEER) dataset from 2000 through 2019. We included all adult patients who received primary surgical resection for histologically confirmed treatment naive HNMCC. Entropy balancing was used to reweight observations such that there was covariate balance between patients who received PORT and patients who received surgical resection alone...
February 24, 2024: Laryngoscope
https://read.qxmd.com/read/38398178/atoh1-tfap2b-and-ceacam6-as-immunohistochemical-markers-to-distinguish-merkel-cell-carcinoma-and-small-cell-lung-cancer
#24
JOURNAL ARTICLE
Serena M Vilasi, Jannett Nguyen, Catherine J Wang, Lingling Miao, Kenneth Daily, Mary Eid, Joon Seon Song, Hong Jiang, Kris Ylaya, Klaus J Busam, Maria R Gaiser, Stephen M Hewitt, Isaac Brownell
Merkel cell carcinoma (MCC) and small cell lung cancer (SCLC) can be histologically similar. Immunohistochemistry (IHC) for cytokeratin 20 (CK20) and thyroid transcription factor 1 (TTF-1) are commonly used to differentiate MCC from SCLC; however, these markers have limited sensitivity and specificity. To identify new diagnostic markers, we performed differential gene expression analysis on transcriptome data from MCC and SCLC tumors. Candidate markers included atonal BHLH transcription factor 1 (ATOH1) and transcription factor AP-2β (TFAP2B) for MCC, as well as carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) for SCLC...
February 15, 2024: Cancers
https://read.qxmd.com/read/38396897/pathophysiology-histopathology-and-differential-diagnostics-of-basal-cell-carcinoma-and-cutaneous-squamous-cell-carcinoma-an-update-from-the-pathologist-s-point-of-view
#25
JOURNAL ARTICLE
Iuliu Gabriel Cocuz, Maria Cătălina Popelea, Raluca Niculescu, Andrei Manea, Adrian-Horațiu Sabău, Andreea-Cătălina Tinca, Andreea Raluca Szoke, Corina Eugenia Budin, Adina Stoian, Silviu Horia Morariu, Titiana Cornelia Cotoi, Maria-Elena Cocuz, Ovidiu Simion Cotoi
Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most frequently occurring non-melanocytic skin cancers. The objective of our study is to present the pathophysiology of BCC and cSCC and its direct relationship with the histopathological diagnostics and the differential diagnostics of these types of cancer, based on the morphological characteristics, immunohistochemical profile, and genetic alterations. The qualitative study was based on emphasizing the morphological characteristics and immunohistochemistry profiles of BCC and cSCC and the differential diagnostics based on the tissue samples from the Clinical Pathology Department of Mures Clinical County Hospital between 2020 and 2022...
February 13, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38394478/incidental-discovery-of-merkel-cell-carcinoma-during-mohs-micrographic-surgery-for-basal-cell-carcinoma-and-squamous-cell-carcinoma-in-situ
#26
JOURNAL ARTICLE
George M Jeha, Lisa Fronek, Hubert T Greenway, Benjamin Kelley
No abstract text is available yet for this article.
February 23, 2024: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://read.qxmd.com/read/38391034/why-do-we-distinguish-between-virus-positive-and-virus-negative-merkel-cell-carcinoma
#27
EDITORIAL
Furkan Bahar, James A DeCaprio
No abstract text is available yet for this article.
February 23, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38390567/conditional-survival-analysis-and-dynamic-prediction-of-long-term-survival-in-merkel-cell-carcinoma-patients
#28
JOURNAL ARTICLE
Jin Zhang, Yang Xiang, Jiqiu Chen, Lei Liu, Jian Jin, Shihui Zhu
BACKGROUND: Merkel cell carcinoma (MCC) is a rare type of invasive neuroendocrine skin malignancy with high mortality. However, with years of follow-up, what is the actual survival rate and how can we continually assess an individual's prognosis? The purpose of this study was to estimate conditional survival (CS) for MCC patients and establish a novel CS-based nomogram model. METHODS: This study collected MCC patients from the Surveillance, Epidemiology, and End Results (SEER) database and divided these patients into training and validation groups at the ratio of 7:3...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38389280/trps1-expression-in-non-melanocytic-cutaneous-neoplasms-an-immunohistochemical-analysis-of-200-cases
#29
JOURNAL ARTICLE
Yi A Liu, Phyu P Aung, Yunyi Wang, Jing Ning, Priyadharsini Nagarajan, Jonathan L Curry, Carlos A Torres-Cabala, Doina Ivan, Victor G Prieto, Qingqing Ding, Woo Cheal Cho
BACKGROUND: Although trichorhinophalangeal syndrome type 1 (TRPS1) was initially thought to be highly sensitive and specific for carcinomas and mesenchymal tumors of mammary origin, more recent data suggest its expression is not limited to breast neoplasms but also can be seen in other cutaneous neoplasms, such as extramammary Paget disease and squamous cell carcinoma (SCC) in situ. METHODS: Two-hundred cases of non-melanocytic cutaneous neoplasm, including basal cell carcinomas (BCCs) (n = 41), SCCs (n = 35), Merkel cell carcinomas (MCCs) (n = 25), and adnexal neoplasms (n = 99), were tested for TRPS1 expression using a monoclonal anti- TRPS1 rabbit anti-human antibody...
February 26, 2024: Journal of Pathology and Translational Medicine
https://read.qxmd.com/read/38384118/the-cutler-beard-flap-for-upper-eyelid-reconstruction-surgical-indications-revisited
#30
JOURNAL ARTICLE
Elia Franzolin, Flavia Quaranta Leoni, Francesco M Quaranta Leoni
PURPOSE: To present the long-term outcome of the Cutler-Beard two-stage technique in patients with large full-thickness upper eyelid defects after tumor excision. METHODS: The medical records of 24 patients with large full-thickness upper eyelid defects reconstructed with the Cutler-Beard technique from January 2000 to January 2021 were retrospectively reviewed. All the defects involved ≥ 60% of the horizontal length of the upper eyelid and extended vertically for at least 15 mm from the eyelid margin...
February 21, 2024: European Journal of Ophthalmology
https://read.qxmd.com/read/38382516/double-primary-cancers-of-earlobe-merkel-cell-carcinoma-and-lung-adenocarcinoma
#31
JOURNAL ARTICLE
Kyung Il Jang, So Yun Lim, Jeon Mi Lee, Eun-Ju Jeon, Hyun Jin Lee
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma with a high rate of metastasis. MCC is rarely suspected during clinical examination, thus requiring biopsy to establish a pathologic diagnosis. In addition, MCC sometimes occurs in double primary cancers. Although there have been reviews on double primary cancers, only a few cases involving MCC have been described. Herein, we report a case of a 54-year-old female patient who presented to our clinic with a diagnosis of earlobe MCC following an excisional biopsy performed by another clinic...
February 22, 2024: Journal of Audiology & Otology
https://read.qxmd.com/read/38366757/incidence-and-survival-rates-of-primary-cutaneous-malignancies-in-korea-1999-2019-a-nationwide-population-based-study
#32
JOURNAL ARTICLE
Soon-Hyo Kwon, Sangmin Choi, Joung Soo Kim, Sang Seok Kim, Mihn-Sook Jue, Soo Hong Seo, Jihye Park, Mi Ryung Roh, Je-Ho Mun, Jun Young Kim, Jee Woong Choi, Ji Won Byun, Sanghyun Park, Min Sung Kim, Seok-Jong Lee
Primary cutaneous malignancies are among the most commonly diagnosed types of cancer worldwide. We aimed to examine the incidence and 5-year survival rates of all types of primary cutaneous malignancies in the Korean population. Data from the Korean Nationwide Cancer Registry from 1999 to 2019 were analyzed. The crude incidence rates, age-standardized incidence rates, and 5-year relative survival rates of each type of skin cancer were calculated. A total of 89 965 patients were diagnosed with primary cutaneous malignancies, which was a 7-fold increase from 1999 to 2019...
February 17, 2024: Journal of Dermatology
https://read.qxmd.com/read/38353321/the-diagnostic-utility-of-merkel-cell-polyoma-virus-immunohistochemistry-in-cytology-specimens
#33
JOURNAL ARTICLE
Aysha Mubeen, Jeffrey K Mito
OBJECTIVE: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine neoplasm that predominantly affects elderly and immunocompromised patients. Merkel cell polyoma virus (MCPyV) is clonally integrated into the majority of MCCs and has been linked to patient outcomes, playing a central role in the pathogenesis of the disease. We aimed to assess the utility of MCPyV immunohistochemistry (IHC) in the diagnosis of MCC in cytology cell block specimens and correlating with clinicopathologic features...
February 14, 2024: Cytopathology: Official Journal of the British Society for Clinical Cytology
https://read.qxmd.com/read/38349855/avelumab-in-the-treatment-of-advanced-merkel-cell-carcinoma-a-systematic-review
#34
JOURNAL ARTICLE
Ajay N Sharma, Karishma S Shah, Aditi A Sharma, Siegrid S Yu
BACKGROUND: Avelumab, a programmed death ligand-1 inhibitor, has shown success in providing durable responses for difficult-to-treat Merkel cell carcinomas (MCCs). OBJECTIVE: Evaluate the efficacy and safety of avelumab in the treatment of advanced MCC. METHODS: Studies reporting the use of avelumab as a monotherapy or in combination with other agents in the treatment of stage III or IV (advanced) MCC were included. The primary outcomes were overall response rate, overall survival (OS), and treatment-related adverse events...
February 13, 2024: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://read.qxmd.com/read/38349538/high-volume-facilities-are-significantly-more-likely-to-use-guideline-adherent-systemic-immunotherapy-for-metastatic-merkel-cell-carcinoma-implications-for-cancer-care-regionalization
#35
JOURNAL ARTICLE
Shayan Cheraghlou, Vartan Pahalyants, Neil K Jairath, Nicole A Doudican, John A Carucci
Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer with a high rate of mortality. While still relatively rare, the incidence of MCC has been rapidly rising in the US and around the world. Since 2017, two immunotherapeutic drugs, avelumab and pembrolizumab, have been FDA-approved for the treatment of metastatic MCC and have revolutionized outcomes for MCC. However, real-world outcomes can differ from clinical trial data, and the adoption of novel therapeutics can be gradual. We aimed to characterize the treatment practices and outcomes of patients with metastatic MCC across the US...
February 13, 2024: Archives of Dermatological Research
https://read.qxmd.com/read/38340724/merkel-cell-polyomavirus-specific-and-cd39-cla-cd8-t%C3%A2-cells-as-blood-based-predictive-biomarkers-for-pd-1-blockade-in-merkel-cell-carcinoma
#36
JOURNAL ARTICLE
Heeju Ryu, Timothy M Bi, Thomas H Pulliam, Korok Sarkar, Candice D Church, Nandita Kumar, Koshlan Mayer-Blackwell, Saumya Jani, Nirasha Ramchurren, Ulla K Hansen, Sine R Hadrup, Steven P Fling, David M Koelle, Paul Nghiem, Evan W Newell
Merkel cell carcinoma is a skin cancer often driven by Merkel cell polyomavirus (MCPyV) with high rates of response to anti-PD-1 therapy despite low mutational burden. MCPyV-specific CD8 T cells are implicated in anti-PD-1-associated immune responses and provide a means to directly study tumor-specific T cell responses to treatment. Using mass cytometry and combinatorial tetramer staining, we find that baseline frequencies of blood MCPyV-specific cells correlated with response and survival. Frequencies of these cells decrease markedly during response to therapy...
January 30, 2024: Cell reports medicine
https://read.qxmd.com/read/38340723/circulating-cancer-specific-cd8-t%C3%A2-cell-frequency-is-associated-with-response-to-pd-1-blockade-in-merkel-cell-carcinoma
#37
JOURNAL ARTICLE
Thomas Pulliam, Saumya Jani, Lichen Jing, Heeju Ryu, Ana Jojic, Carolyn Shasha, Jiajia Zhang, Rima Kulikauskas, Candice Church, Charlie Garnett-Benson, Ted Gooley, Aude Chapuis, Kelly Paulson, Kellie N Smith, Drew M Pardoll, Evan W Newell, David M Koelle, Suzanne L Topalian, Paul Nghiem
Understanding cancer immunobiology has been hampered by difficulty identifying cancer-specific T cells. Merkel cell polyomavirus (MCPyV) causes most Merkel cell carcinomas (MCCs). All patients with virus-driven MCC express MCPyV oncoproteins, facilitating identification of virus (cancer)-specific T cells. We studied MCPyV-specific T cells from 27 patients with MCC using MCPyV peptide-HLA-I multimers, 26-color flow cytometry, single-cell transcriptomics, and T cell receptor (TCR) sequencing...
February 9, 2024: Cell reports medicine
https://read.qxmd.com/read/38338862/prame-updated-diagnostic-prognostic-and-therapeutic-role-in-skin-cancer
#38
REVIEW
Fortunato Cassalia, Andrea Danese, Ina Tudurachi, Serena Federico, Anna Zambello, Alessia Guidotti, Ludovica Franceschin, Anna Bolzon, Luigi Naldi, Anna Belloni Fortina
Preferentially Expressed Antigen in Melanoma (PRAME), a member of the cancer/testis antigen family, is central to the field of skin cancer diagnostics and therapeutics. As a nuclear receptor and transcriptional regulator, PRAME plays a critical role in inhibiting retinoic acid signalling, which is essential for cell differentiation and proliferation. Its aberrant overexpression in various malignancies, particularly cutaneous melanoma, is associated with more aggressive tumour phenotypes, positioning PRAME as both a diagnostic and prognostic marker...
January 27, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38331456/sstr-antagonists-as-theranostic-option-in-merkel-cell-carcinoma
#39
JOURNAL ARTICLE
Malte Kircher, Adriana Amerein, Mareike Augustin, Nic G Reitsam, Johanna S Enke, Marianne Patt, Georgine Wienand, Ralph A Bundschuh, Christian H Pfob, Constantin Lapa, Alexander Dierks
No abstract text is available yet for this article.
February 8, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38325726/merkel-cell-carcinoma-and-the-eye
#40
JOURNAL ARTICLE
Rodolfo Valentini, Jane M Grant-Kels, Madina Falcone, Campbell L Stewart
Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine tumor with a poor five year survival rate. Yearly cases have risen nearly 350% since the early 1980's, and these are predicted to increase as the overall U.S. population ages. MCC of the eyelid is uncommon and can be misdiagnosed as other benign inflammatory and neoplastic eyelid disorders. While MCC of the head and neck is often more aggressive than other sites, eyelid MCC shows a lower disease specific mortality rate. A biopsy is essential for accurate diagnosis, including an immunohistochemical panel of CK20 and TTF-1, although other markers may be necessary...
February 5, 2024: Clinics in Dermatology
keyword
keyword
5085
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.